摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(7RS,9ASR)-7-hydroxymethyl-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine

中文名称
——
中文别名
——
英文名称
(7RS,9ASR)-7-hydroxymethyl-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine
英文别名
cis-7-hydroxymethyl-2,3,4,6,7,8,9,9a-octahydro-2H-pyrido[1,2-a]pyrazine;cis-7-Hydroxymethyl-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;trans-7-(hydroxymethyl)octahydro-2H-pyrido(1,2-a)pyrazine;2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-7-ylmethanol
(7RS,9ASR)-7-hydroxymethyl-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine化学式
CAS
——
化学式
C9H18N2O
mdl
——
分子量
170.255
InChiKey
IUKDDYAECHPPRM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    35.5
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Bis-aza-bicyclic anxiolytic agents
    申请人:Pfizer Inc.
    公开号:US05122525A1
    公开(公告)日:1992-06-16
    Anxiolytic agents which are racemic or optically active pyrido[1,2-a]pyrazine derivatives of the formula ##STR1## wherein x is N or CH and Y represents one of certain pyrazolo, triazolo, tetrazolo or cyclic imido radicals; and intermediates therefor.
    抗焦虑剂是拥有手性或非手性吡啶[1,2-a]吡嗪衍生物,其化学式为##STR1##其中x为N或CH,Y代表某些嘧唑啉、三唑啉、四唑啉或环状亚酰胺基团;以及其中间体。
  • [EN] BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS
    申请人:PFIZER INC.
    公开号:WO1990008144A1
    公开(公告)日:1990-07-26
    (EN) Anxiolytic agents which are racemic or optically active pyrido[1,2-a]pyrazine derivatives of formula (I), wherein X is N or CH and Y represents one of certain pyrazolo, triazolo, tetrazolo or cyclic imido radicals; and intermediates therefor.(FR) On décrit des agents anxiolytiques qui sont racémiques ou des dérivés optiquement actifs de pyrido(1,2-a)pyrazine ayant la formule (I) selon laquelle X constitue N ou CH et Y représente un radical parmi certains radicaux de pyrazole, de triazole, de tétrazole ou d'imide cyclique; et des intermédiaires de ceux-ci.
    一种具有式(I)的手性或外消旋的吡啶[1,2-a]吡嗪衍生物的抗焦虑剂,其中X为N或CH,Y代表某些嘧啶唑,三唑,四唑或环状亚酰胺基团之一;以及其中间体。
  • Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
    申请人:Pfizer Inc.
    公开号:US05157034A1
    公开(公告)日:1992-10-20
    Antipsychotic compounds having the formula ##STR1## wherein Z is H or Cl; Y is O or S; n is 1-4; separately, X is H or (C.sub.1 -C.sub.2)alkyl and L is R(CH.sub.2).sub.m CO, m is 0 or 1-3, R is (C.sub.1 -C.sub.6)alkyl, (C.sub.3 -C.sub.7)cycloalkyl, phenyl, naphthyl, furyl, benzofuranyl, thienyl, benzothienyl, pyrrolyl, indolyl, isoindolyl or one of said groups substituted on aromatic or heteroaromatic ring with fluoro, chloro, (C.sub.1 -C.sub.2)alkyl or (C.sub.1 -C.sub.2)alkoxy; or together L and X, in combination with the nitrogen to which they are attached, form certain cyclic imides, 4-substituted piperidines or a cyclic sulfonamide.
    具有以下式子的抗精神病化合物:##STR1## 其中,Z为H或Cl; Y为O或S; n为1-4; 分别,X为H或(C.sub.1-C.sub.2)烷基,L为R(CH.sub.2).sub.m CO,m为0或1-3,R为(C.sub.1-C.sub.6)烷基,(C.sub.3-C.sub.7)环烷基,苯基,萘基,呋喃基,苯并呋喃基,噻吩基,苯并噻吩基,吡咯基,吲哚基,异吲哚基或其中一种被氟、氯、(C.sub.1-C.sub.2)烷基或(C.sub.1-C.sub.2)烷氧基取代的芳香或杂芳环上的基团;或者L和X在与它们附着的氮原子结合时,形成某些环酰亚胺,4-取代哌啶或环磺酰胺。
  • 2,7-Substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors
    申请人:——
    公开号:US20040214830A1
    公开(公告)日:2004-10-28
    Substituted pyrido[1,2-a]pyrazines of general formula I; wherein Ar and Ar 1 represent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO 2 , CHOH, C═O, or —(CR 3 R 4 ); and n is 0-2, as well as precursors thereto, are ligands for dopamine receptor subtypes and serotonin (5HT) within the body and are therefore useful in the treatment of disorders of the dopamine and serotonin systems: 1
    通式I的取代吡啶[1,2-a]吡嗪,其中Ar和Ar1代表各种碳环和杂环芳香环;A代表O,S,SO,SO2,CHOH,C═O或—(CR3R4);n为0-2,以及其前体,是体内多巴胺受体亚型和5-羟色胺(5HT)的配体,因此在治疗多巴胺和5-羟色胺系统紊乱方面有用:1
  • Process for preparing trans-piperidine-2,5-dicarboxylates
    申请人:Pfizer Inc.
    公开号:US05637713A1
    公开(公告)日:1997-06-10
    Process for the preparation of a dialkyl trans-piperidine-2,5-dicarboxylate from a corresponding dialkyl cis-piperidine-2,5-dicarboxylate via a trans-substituted pyridine derivative of the formula ##STR1## wherein R is a (C.sub.1 -C.sub.3)alkyl group.
    从相应的二烷基顺式-哌啶-2,5-二羧酸二烷酯经由一种公式为##STR1##的顺式取代吡啶衍生物制备二烷基反式-哌啶-2,5-二羧酸二烷酯的方法,其中R为(C.sub.1-C.sub.3)烷基。
查看更多

同类化合物

麦可弗汀A 六氢-2-甲基-2H-吡啶并[1,2-a]吡嗪-1,6-二酮 八氢吡啶并〔1,2-A〕吡嗪-6-酮 八氢吡啶并[1,2-a]吡嗪 八氢-吡啶并[1,2-A]吡嗪-4-酮盐酸盐 八氢-3-甲基-2H-吡啶并[1,2-a]吡嗪 八氢-2H-吡啶并[1,2-a]吡嗪-6-甲醇 7-甲氧基辛a氢-2H-吡啶并[1,2-a]吡嗪-2-胺 7-乙基八氢-2H-吡啶并[1,2-a]吡嗪-2-胺 6-甲基八氢-2H-吡啶并[1,2-a]吡嗪-2-胺 4H-吡唑[1,2-A]吡嗪-4-八氢酮 3-甲基八氢-2H-吡啶并[1,2-a]吡嗪-2-胺 2-苄基八氢-1H-吡啶并[1,2-a]吡嗪 2-硝基八氢-2H-吡啶并[1,2-a]吡嗪 2-乙基六氢-2H-吡啶并[1,2-a]吡嗪-1(6H)-酮 2-(9-甲基-3,9-二氮杂双环[3.3.1]壬-3-基)乙胺 2-(4-甲硫基唑-5-基)乙基丁酸酯 2,3,4,6,7,8,9,9alpha-八氢-1H-吡啶并[1,2-a]吡嗪-3-基甲醇 1,1'-联苯基,2-乙基-5-甲氧基- (R)-八氢吡啶并[1,2-A〕吡嗪二盐酸盐 (9aS)-八氢-4H-吡啶并[1,2-a]吡嗪-4-酮 (9aR)-八氢-2H-吡啶并[1,2-a]吡嗪 (9SS)-八氢-2-吡啶-吡嗪盐酸盐[1,2-A] (7r,9as)-八氢-2H-吡啶并[1,2-a]吡嗪-7-甲醇 (3S,6S)-3-苄基-1,4-二氮杂双环[4.4.0]癸烷-2,5-二酮 ((7S,9as)-八氢-1H-吡啶并[1,2-a]吡嗪-7-基)甲醇 ((6R,9as)-八氢-1H-吡啶并[1,2-a]吡嗪-6-基)甲醇 (S)-octahydro-2H-pyrido[1,2-a]pyrazine dihydrochloride (7R,9AS)-trans-(2,5-Difluoro-phenyl)-[7-(3-pyrrolidin-1-ylmethyl-phenoxymethyl)-octahydro-pyrido[1,2-a]pyrazin-2-yl]-methanone oxime (7RS,9ASR)-7-hydroxymethyl-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine (6aα,10aα,11aα)-1,3,4,6,6a,7,8,9,10,10a,11,11a-Dodecahydro-2H-pyrazino-[1,2-b]isoquinoline-1,3-dione 17-β-cyanomarcfortine A 17-α-cyanomarcfortine A marcfortine A (trans)-benzyl 7-(8-chloroimidazo[1,5-a]pyrazin-3-yl)-4-oxohexahydro-1H-pyrido[1,2-a]pyrazine-2(6H)-carboxylate 3,5-dibromo-N-{(2S)-2-(4-fluorophenyl)-4-[3-(octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)-azetidin-1-yl]butyl}-N-methylbenzamide acetate 2H-Pyrido[1,2-a]pyrazine, 2-[1-(3-fluorophenyl)ethyl]octahydro-3-methyl- 3-(4-octahydro-2H-pyrido[1,2-a]pyrazin-2-ylbutoxy)benzonitrile 1-[(7R,9aS)-2-BOC-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-7-ylmethyl]-1,3-dihydro-indol-2-one 2-<2-(3-indolyl)ethyl>-3-hydroxy-1-oxo-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido<1.2-a>pyrazine 2-<2-(3-indolyl)ethyl>-1-hydroxy-3-oxo-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido<1.2-a>pyrazine (1R,3R)-11,14-Dihydroxy-16-(hydroxymethyl)-13-methoxy-12,20-dimethyl-5-oxa-8,17,20-triazahexacyclo[15.3.1.03,19.04,8.09,18.010,15]henicosa-10(15),11,13-triene-21-carbonitrile trans-perhydrodiazaphenanthrene cis-perhydrodiazaphenanthrene tert-butyl (1aR,4S,6aR,7aR)-4-{[(1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}octahydro-5H-cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-5-carboxylate 2-benzyl-hexahydro-6H-pyrido[1,2-a]pyrazine-1,4-dione (7R,9aS)-2-BOC-7-(4-fluorophenoxy)methyl-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine trans-7-(3-piperidin-1-ylpropoxymethyl)-octahydro-pyrido[1,2-a]pyrazine-2-carboxylic acid tert-butyl ester 2-(2-Fluoro-benzenesulfonyl)-octahydro-pyrido[1,2-a]pyrazin-6-one (3S,6R)-3-Benzyl-1,4-diazabicyclo<4.4.0>decane-2,5-dione